Standard pen test scoping frameworks weren't built for pharma. Learn how to scope an engagement that covers validated systems under 21 CFR Part 11 and protects high-value formulation and clinical data from targeted threats.

Completing a pen test isn't enough for CMMC. Learn what C3PAO assessors actually look for in your evidence package and how to align your report, scope, POA&M, and remediation docs to specific practice statements.

21 CFR Part 11 and cGMP don't mention penetration testing but the controls they require depend on it. Learn how to align your pharma pen test program with regulatory requirements and prepare for FDA data integrity inspections.

R&D and GxP regulated environments have different risk profiles, compliance requirements, and testing constraints. Learn why a single unified pen test scope fails both and how to run dual-scope engagements efficiently.

Nation-state actors treat pharma like critical infrastructure targeting formulation data, synthesis routes, and clinical IP with patience and precision. Learn why standard pen testing misses this threat and what adversary simulation reveals instead.